吉林中医药2025，Vol.45Issue(6)：689-694,6.DOI:10.13463/j.cnki.jlzyy.2025.06.017
二参真武汤治疗心肾阳虚型慢性心力衰竭的疗效分析
Analysis of the therapeutic effect of Ershen Zhenwu Tang in the treatment of chronic heart failure with the syndrome of yang deficiency of the heart and kidney
摘要
Abstract
Objective To explore the therapeutic effect of Ershen Zhenwu Tang in the treatment of chronic heart failure(CHF)with the syndrome of yang deficiency of both the heart and the kidney.Methods A total of 112 elderly CHF patients with the syndrome of yang deficiency of the heart and kidney,who received a treatment at the Taihe Traditional Chinese Medicine Hospital Affiliated to Anhui University of Chinese Medicine from January 2022 to March 2024,were randomly divided into an observation group and a control group using a random number table method,with 56 cases in each group.The control group was treated with Sacubitril Valsartan Sodium Tablets,while the observation group was treated with Ershen Zhenwu Tang on the basis of that.After 4 weeks of treatment,the traditional Chinese medicine syndrome scores,the levels of left ventricular ejection fraction(LVEF),left ventricular end-systolic/diastolic diameter(LVESD/LVEDD),N-terminal proBNP precursor(NT proBNP),homocysteine(HCY),angiotensin II(AngII),aldosterone(ALD),cardiac output per stroke,blood output,and peripheral resistance were compared between the two groups to evaluate their therapeutic effects and adverse reactions.Results After treatment,the main syndrome scores of the observation group and the control group were respectively(6.72±1.13)and(7.21±1.06)points,while their secondary syndrome scores were(2.47±0.65)and(3.02±0.59)points,and the tongue and pulse scores were(1.97±0.46)and(2.23±0.51)points,the LVEF was(54.16±6.08)versus(51.18±7.43)%,the LVESD was(47.68±5.15)versus(50.16±6.34)mm,and the LVEDD was(58.32±5.81)versus(61.27±5.43)mm,NT proBNP was(759.63±154.32)versus(841.35±169.71)pg/mL,HCY values were(13.24±2.56)versus(15.87±3.01)µmol/L,AngII was(65.13±21.46)versus(89.96±26.71)pg/mL,ALD was(72.37±25.18)versus(90.14±23.57)pg/mL,the cardiac output per stroke was(67.43±6.15)vs(63.51±5.84)mL,the blood output was(4.23±0.95)vs(3.61±0.72)L/min,the peripheral resistance was(1702.31±251.69)vs(1858.37±263.41)kPa·s/L,and the treatment efficacy was 92.86%vs 78.57%,with statistically significant differences(P<0.05).After treatment,the scores of the main and secondary syndromes,tongue and pulse,NT proBNP and HCY,ALD and AngII were decreased in both groups,and the observation group was lower than the control group(P<0.05).During the treatment period,no serious adverse reactions occurred in both groups.Conclusion In the treatment of elderly CHF patients with the syndrome of yang deficiency of both the heart and the kidney,the combination of Ershen Zhenwu Tang and Sacubitril Valsartan Sodium Tablets can help regulate the expression of NT proBNP,HCY,AngII,and improve heart function.关键词
慢性心力衰竭/老年/心肾阳虚型/二参真武汤/沙库巴曲缬沙坦钠片/心功能Key words
chronic heart failure/elderly/syndrome of yang deficiency of heart and kidney/Ershen Zhenwu Tang/Sacubitril Valsartan Sodium Tablets/cardiac function分类
医药卫生引用本文复制引用
张明明,倪代梅,付小奎,孙玉,葛岚..二参真武汤治疗心肾阳虚型慢性心力衰竭的疗效分析[J].吉林中医药,2025,45(6):689-694,6.基金项目
安徽省卫生健康科研项目(AHWJ2023A10087) （AHWJ2023A10087）
